Dr. Rajesh Kumar Jain

Dr. Rajesh Kumar Jain is a Principal Director of Surgical Oncology at BLK-Max Super Speciality Hospital in New Delhi, with more than 28 years of clinical experience in cancer surgery. He holds MBBS, MS (General Surgery), and DNB (Surgical Oncology) qualifications, positioning him as a highly trained specialist in the management of complex oncological cases across multiple organ systems.

Dr. Jain's clinical expertise spans the full spectrum of surgical oncology, including breast cancer, lung cancer, head and neck malignancies, thyroid cancer, renal cell carcinoma, colorectal cancer, bone tumours, soft tissue sarcomas, ovarian cancer, cervical cancer, and advanced procedures such as cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). Throughout his career, he has refined his surgical techniques and remains dedicated to delivering precise, compassionate cancer care. His experience includes management of both adult and paediatric oncology cases, as well as robotic-assisted cancer surgery.

Dr. Jain regularly treats international patients from the Gulf region, Africa, and across South Asia who seek cutting-edge surgical oncology care. He understands the logistical and emotional needs of patients travelling for treatment and coordinates comprehensive pre-operative evaluation, surgical planning, and follow-up care. His fluency in English and Hindi ensures clear communication with diverse patient populations.

BLK-Max Super Speciality Hospital, where Dr. Jain leads the surgical oncology department, is a leading cancer and multispeciality centre in Delhi equipped with state-of-the-art operating theatres, advanced imaging, and dedicated oncology wards. The hospital maintains NABH accreditation and offers robust international patient support services, making it an ideal destination for international medical tourists seeking world-standard cancer treatment.

International patients considering surgery under Dr. Jain's care benefit from his decades of institutional experience, his membership in the Indian Society of Oncology, and the comprehensive multidisciplinary tumour board approach at BLK-Max, where each case is reviewed collaboratively to ensure optimal outcomes.